0001193125-26-079167
SEC filingTreace Medical Concepts, Inc. (TMCI) reported FY 2025 revenue of $212.7 million, up 1.6% from $209.4 million in FY 2024, driven by increased bunion procedure kit sales despite lower average selling prices from new minimally invasive products. Gross profit rose 0.9% to $169.8 million, with gross margin slightly declining to 79.8% from 80.4% due to stocking distributor sales and inventory provisions. Operating expenses remained stable at $223.9 million, reflecting sales and marketing reductions offset by higher G&A from litigation. Loss from operations improved 2.8% to -$54.2 million. Net loss widened 5.8% to -$59.0 million, or -$0.93 per share, from -$55.7 million, or -$0.90 per share, impacted by $2.7 million debt extinguishment loss and lower interest income. Cash used in operations was $16.0 million, better than $37.2 million prior year, with net cash decrease of $0.6 million. Balance sheet shows $190.6 million total assets, $87.3 million equity, and $55.6 million long-term debt. New $175 million credit facility provides liquidity amid macroeconomic pressures and competition in bunion surgery market.
Treace Medical Concepts reported FY 2025 revenue of $212.7 million, a modest 1.6% increase from $209.4 million in FY 2024, primarily from higher bunion procedure kit volumes offset by lower pricing on new osteotomy systems. Gross profit grew 0.9% to $169.8 million, though margins dipped to 79.8% from 80.4% due to distributor sales and inventory charges. Operating expenses held steady at $223.9 million, with sales/marketing down 4.6% from DTC cuts but G&A up 12.6% from litigation. Operating loss narrowed 2.8% to -$54.2 million. Net loss expanded 5.8% to -$59.0 million (-$0.93/share) from debt refinancing costs and lower interest income. Cash burn improved, with operating cash use at -$16.0 million vs -$37.2 million prior year. Balance sheet reflects $190.6 million assets, $87.3 million equity, $10.7 million cash equivalents. New $175M credit facility enhances liquidity amid elective procedure softness.
Revenue reached $212.7 million (+1.6% YoY), driven by bunion kit sales growth despite Lapiplasty declines from competition and osteotomy shifts. $13.0 million from new stocking distributors (initial stocking). No segment breakdowns disclosed; focus on U.S. direct sales (80% employee-driven). Active surgeons rose 6% to 3,337. Macro pressures and ambulatory surgery shifts pressured volumes.
Gross margin contracted to 79.8% from 80.4%, impacted by distributor discounts and $2.9 million inventory provisions (up from $1.8 million). Sales/marketing fell 4.6% to $140.9 million via DTC reductions; R&D stable at $20.3 million; G&A rose 12.6% to $62.7 million from $5.4 million litigation fees. Operating loss improved to -$54.2 million. Net loss widened from $2.7 million debt loss, $5.3 million interest expense.
Operating cash use narrowed to -$16.0 million from -$37.2 million, aided by $33.8 million share-based comp and working capital shifts. Investing yielded $13.3 million net from securities; financing $2.1 million from new debt. Cash equivalents $10.7 million (down from $11.4 million); total current assets $132.1 million; inventories $36.0 million. Total assets $190.6 million; long-term debt $55.6 million post-refinancing; equity $87.3 million; accumulated deficit -$249.0 million.
Management highlights new products (Nanoplasty, Percuplasty, SpeedMTP) gaining traction amid Lapiplasty slowdowns. Macro challenges (inflation, deductibles) and competition persist. New $175M facility (Tranche 1 drawn) supports growth; future tranches tied to revenue. Focus on sales optimization, surgeon training. Risks: elective procedure demand, IP litigation, cash burn.